SBIR/STTR Research Award

Renal Perfusion Quantification With 62CU PET

Award identifier 8a21b51bdabe35012f12ccc08fcb229877efa0c5802b7440e227ade76ec01af0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,963,226

Program and phase

SBIR · Phase II

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PROPORTIONAL TECHNOLOGIES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
TAPPXED88F63
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Serious kidney disease, involving substantial impairment of function, affects approximately 3.5 million Americans. Quantitative measurement of regional and global renal perfusion can provide important diagnostic information in the evaluation of such patients. Despite an intense search within the research community for a suitable non-invasive method for such measurements, existing techniques have severe limitations including lack of quantification (MRI), dependence on highly skilled users (color Doppler) or inappropriateness for use in humans (radiolabeled microspheres). Although global kidney function can be assessed using clearance indicators, these techniques provide no direct perfusion information. With a suitable radioactive agent, PET imaging can provide absolute quantification of regional blood flow with excellent spatial resolution and can be applied conveniently in humans. We propose to employ the PET agent 62Cu-ETS for this unique renal application. This agent has a short 9.7minute physical half-life, permitting safe, repeated use in humans and can be nationally distributed through use of a PTI developed generator. In our Phase I studies, this agent has demonstrated uniquely high renal uptake in humans and also demonstrated linear uptake to very high renal flow levels in a pig model. The proposed Phase II work will involve refinement of the radiochemical process for clinical production of the 62Cu-ETS and the necessary work for submission of an Investigational New Drug Application. In addition we will continue our work in Phase I by validating the application of 62Cu-ETS for PET quantification of regional renal perfusion in a pig model of acute focal renal injury, as well as translating the model to 62Cu-ETS quantification of regional renal perfusion in humans. Given the strength of PET and the characteristics of the Cu-ETS tracer, this imaging procedure can provide an ideal non-invasive technique for absolute quantitative measurement of both regional and global renal blood flow with far-reaching benefits in patient management and diagnosis.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

55 SBIR/STTR records share this UEI (1994–2023). Reported award amounts total $25,350,343. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Energy, Department of Defense, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.